<DOC>
	<DOC>NCT02053064</DOC>
	<brief_summary>P2-SAF-301 is an open-label interventional study without administration of investigational product, evaluating the long-term safety and tolerability of intracerebral SAF-301 previously administered to 4 patients with Sanfilippo type A syndrome. The primary objective is to collect additional safety and tolerability data on intracerebral SAF-301 previously administered to 4 patients with Sanfilippo type A syndrome. The secondary objective is to further collect data to assess the effects of SAF-301 on neurological and psychological status, and potential biological markers.</brief_summary>
	<brief_title>Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Patients having completed the previous phase I/II study (P1SAF301), Family understanding the followup procedures and the informed consent, Patient's parents having signed the informed consent form. Participation in any other clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neurodegenerative diseases</keyword>
	<keyword>Nervous systems diseases</keyword>
	<keyword>Genetic diseases, Inborn</keyword>
	<keyword>Metabolic diseases</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Adeno Associated Virus (AAV)</keyword>
</DOC>